Published On: 10/31/2018
TARGET PharmaSolutions Initiates a New Community, TARGET-HBV, to Advance the Understanding of Hepatitis B
CHAPEL HILL, NC – (October 31, 2018) – TARGET PharmaSolutions, Inc., a company focused on real world evidence, is pleased to announce that it has started enrolling patients in TARGET-HBV.
TARGET-HBV is an observational study that will conduct a comprehensive review of patients with chronic hepatitis B virus (HBV) infection. TARGET-HBV plans to enroll up to 5,000 patients across a large network of academic and community sites in the United States to advance the understanding of hepatitis B.
Dr. Anna Lok, TARGET-HBV Scientific Advisor, explained “TARGET-HBV is timely given the renewed interest in finding a cure for hepatitis B. Chronic hepatitis B is characterized by fluctuations in virus replication and disease activity; thus, while guidelines exist, management of individual patients can be nuanced. Data on a large cohort of hepatitis B patients managed in the real-world will provide insights into the course of this disease and guide the use of future therapies.”
Meg Powell, Pharm.D., CEO of TARGET PharmaSolutions, stated “We are very excited that we have started enrolling patients in our TARGET-HBV community. We have seen significant interest from investigative sites to participate in this important study, and we look forward to continuing to advance the understanding of this challenging disease.”
TARGET PharmaSolutions provides regulatory grade data and analysis that can be used throughout the pharmaceutical development and commercialization process. The TARGET model organizes a community of stakeholders, including key scientific leaders, regulatory agencies, pharmaceutical manufacturers, and patient advocacy groups, around a specific disease to generate real world evidence about the natural history, current treatment paradigm, and patient outcomes. This model enables TARGET’s stakeholders to answer critical strategic and planning questions.
About TARGET PharmaSolutions
Headquartered in Durham, NC, TARGET PharmaSolutions is a privately held real-world data solutions company that provides pharmaceutical and biotechnology partners a more efficient way to generate data in the real-world setting. TARGET PharmaSolutions has six disease communities: TARGET-NASH (nonalcoholic steatohepatitis), TARGET-PBC (primary biliary cholangitis), TARGET-HCC (hepatocellular carcinoma), TARGET-IBD (inflammatory bowel disease), TARGET-DERM (immune mediated skin conditions) and TARGET-HBV (hepatitis B).
For more information, visit www.targetpharmasolutions.com.
984.234.0268 ext 205
03/17/2020TARGET PharmaSolutions Expands TARGET-DERM Research Community with Two New Industry Partnerships
03/13/2020TARGET PharmaSolutions Launches Real-World Asthma Study
02/20/2020TARGET-IBD Poster & Oral Presentation at ECCO
02/13/2020TARGET PharmaSolutions Appoints Neal Bibeau as Chief Executive Officer